Exercise of Warrants and Issue of Equity

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Exercise of Warrants and Issue of Equity

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has received an exercise notice in respect of warrants (issued in July 2017) to subscribe for 300,000 new ordinary shares of 25 pence in the Company ("New Ordinary Shares"), with an exercise price of 25 pence per share.

Once issued, the New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Application has been made for the 300,000 New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or around 28 September 2021.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 439,489,371 Ordinary Shares of 25 pence each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company will be 439,489,371.

The above figure of 439,489,371 includes the shares which are expected to be admitted to trading on or around 24 September 2021, details of which were announced on 20 September 2021. As also announced on 20 September 2021, a further 11,145,405 Ordinary Shares are expected to be admitted to trading on or around 22 October 2021. Accordingly, the total number of shares issued and admitted to trading on 22 October 2021 will be 450,634,776 Ordinary Shares, assuming no changes to issued share capital in the meantime.

The aforementioned figures may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

- ENDS -

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.